MetaReal Corporation (TYO:6182)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions JPY. Fiscal year is March - February.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 31, 2025	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Market Capitalization	6,652	7,022	17,498	12,452	10,167	27,975
Market Cap Growth	-46.96%	-59.87%	40.53%	22.47%	-63.66%	-4.44%
Enterprise Value	5,136	5,133	16,035	11,765	9,688	27,428
Last Close Price	611.00	645.00	1625.00	1165.00	954.00	2625.00
PE Ratio	31.01	23.49	32.77	429.36	-	-
Forward PE	-	136.53	136.53	105.97	261.18	91.74
PS Ratio	1.63	1.72	4.19	2.90	2.44	6.99
PB Ratio	3.51	3.59	10.41	10.99	9.26	11.42
P/TBV Ratio	5.73	5.87	14.01	26.95	96.83	28.52
P/FCF Ratio	-	-	18.94	24.80	19.55	32.19
P/OCF Ratio	-	115.12	18.82	24.56	19.44	30.98
EV/Sales Ratio	1.26	1.26	3.84	2.74	2.33	6.85
EV/EBITDA Ratio	48.17	13.33	13.55	11.59	13.98	40.22
EV/EBIT Ratio	-	44.25	19.53	22.07	105.30	360.89
EV/FCF Ratio	-	-	17.35	23.44	18.63	31.56
Debt / Equity Ratio	0.76	0.86	0.87	1.54	1.78	0.77
Debt / EBITDA Ratio	13.28	4.37	1.23	1.72	2.83	2.77
Debt / FCF Ratio	-	-	1.58	3.47	3.77	2.17
Asset Turnover	0.86	0.87	0.96	0.94	0.78	0.85
Inventory Turnover	33.03	30.40	79.88	88.59	66.78	61.38
Quick Ratio	1.47	1.57	1.64	1.39	1.14	1.32
Current Ratio	1.60	1.72	1.76	1.50	1.21	1.38
Return on Equity (ROE)	11.55%	16.44%	37.95%	2.60%	-69.80%	-3.77%
Return on Assets (ROA)	-1.83%	1.55%	11.83%	7.30%	1.07%	1.01%
Return on Capital (ROIC)	-2.74%	2.14%	17.06%	11.23%	1.55%	1.43%
Return on Capital Employed (ROCE)	-	4.10%	33.50%	23.90%	3.70%	2.00%
Earnings Yield	3.22%	4.26%	3.05%	0.23%	-12.18%	-0.24%
FCF Yield	-	-2.11%	5.28%	4.03%	5.12%	3.11%
Dividend Yield	-	-	-	-	-	0.23%
Buyback Yield / Dilution	0.08%	-0.09%	-0.12%	-1.90%	1.19%	-1.61%
Total Shareholder Return	-	-0.09%	-0.12%	-1.90%	1.19%	-1.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.